NeuroSense Therapeutics Ltd. (NRSN)

IL — Healthcare Sector
Peers: NRXS  CASI  BOLD  CVKD  KZR  IGC  KLTO  SONN  XCUR  CLGN 

Automate Your Wheel Strategy on NRSN

With Tiblio's Option Bot, you can configure your own wheel strategy including NRSN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NRSN
  • Rev/Share 0.0
  • Book/Share -0.0204
  • PB -59.2224
  • Debt/Equity 0.0
  • CurrentRatio 0.7063
  • ROIC 16.5125

 

  • MktCap 29846666.0
  • FreeCF/Share -0.0002
  • PFCF -7461.6665
  • PE -3.5501
  • Debt/Assets 0.0
  • DivYield 0
  • ROE 27.205

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
NRSN
Published: September 10, 2025 by: PRNewsWire
Sentiment: Neutral

Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile CAMBRIDGE, Mass. , Sept. 10, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

Read More
image for news NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
NRSN
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral

NeuroSense Announces Global CDMO Selection and Manufacturing Scale-Up, Enabling Rapid Pathway to Commercialization for What is Projected to be a $100-150M Canadian Market Opportunity CAMBRIDGE, Mass. , May 7, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

Read More
image for news NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
NRSN
Published: April 24, 2025 by: PRNewsWire
Sentiment: Neutral

Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing partnership discussions with global pharmaceutical company CAMBRIDGE, Mass. , April 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

Read More
image for news NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

About NeuroSense Therapeutics Ltd. (NRSN)

  • IPO Date 2021-12-09
  • Website https://www.neurosense-tx.com
  • Industry Biotechnology
  • CEO Alon Ben-Noon
  • Employees 17
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.